French independent pharma company Pierre Fabre today announced the launch of a new fund to accelerate the clinical development of new products in oncology and dermatology.
The Pierre Fabre Fund for Innovation is intended for bio-pharmaceutical companies, start-ups and research laboratories (public or private), primarily in France and Europe.
Research projects eligible for support will either be fewer than 24 months away from moving from preclinical to clinical development, or will be in the early stage of clinical development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze